5 results on '"Yaman, F."'
Search Results
2. Eltrombopag treatment in thrombocytopenia following hematopoietic stem cell transplantation: A multicenter real-world experience.
- Author
-
Kilic Gunes E, Yigit Kaya S, Yaman F, Yeniay MK, Vural K, Comert M, Sevindik OG, Andic N, Dagdas S, Nizam Ozen I, Kaynar L, Yavasoglu F, Ozet G, Karakus V, and Ayli M
- Subjects
- Humans, Female, Male, Adult, Middle Aged, Retrospective Studies, Young Adult, Adolescent, Aged, Platelet Count, Hydrazines therapeutic use, Hydrazines administration & dosage, Hydrazines adverse effects, Benzoates therapeutic use, Benzoates administration & dosage, Benzoates adverse effects, Pyrazoles therapeutic use, Pyrazoles adverse effects, Pyrazoles administration & dosage, Hematopoietic Stem Cell Transplantation adverse effects, Thrombocytopenia etiology, Thrombocytopenia drug therapy
- Abstract
Introduction: Thrombocytopenia is among the most common complications following hematopoietic stem cell transplantation and is associated with increased mortality and morbidity with no standard treatment yet. In this multicenter and retrospective study, we aim to present our multi-center experience of Eltrombopag treatment in patients with isolated thrombocytopenia following HSCT., Material-Method: A total of 73 patients from 5 centers who underwent autologous or allogeneic stem cell transplantation, had no primary disease relapse, all of whom had neutrophil engraftment, complete chimerism, and who were diagnosed with Prolonged Isolated Thrombocytopenia (PIT) or Secondary Failure Of Platelet Recovery (SFPR) were included in the study. The patients were initiated on Eltrombopag at a dose of 50-150 mg. Complete response was defined as a platelet count >50×10
9 /L for 7 consecutive days with no transfusion support., Results: A total of 50.3% of the patients underwent Autologous and 49.7% Allogeneic Stem Cell Transplantation, 54.8% were diagnosed with PIT, and 45.2% were diagnosed with SFPR, and the treatment with 50-150 mg/day Eltrombopag was initiated on the median day +42. Complete response was achieved in 71.2% of these patients on the median day 23 of the treatment. No significant effects of the initial dose (50-150 mg/day) were detected in the Complete Response in the multivariate analysis on response. An insufficient number of Megakaryocytes in the bone marrow before Eltrombopag treatment was determined as an independent risk factor in determining the response (OR 3.57, 95% CI 1.21-10.55). The overall survival of the patients who did not respond to Eltrombopag was found to be significantly worse than that of patients who responded (p=0.022, HR:2.74, 95% CI 1.12-6.54)., Conclusion: As a result of the present study, Eltrombopag treatment was found to be effective and safe in thrombocytopenia that develops following hematopoietic stem cell transplantation. It was concluded that its use may be more effective in patients with sufficient bone marrow megakaryocytes before the treatment and an initial dose of 50 mg/day may be appropriate in terms of cost, effectiveness, and toxicity. Large-scale randomized and controlled prospective studies are needed to determine the roles of Eltrombopag treatment in patients with post-transplant PIT and SFPR., Competing Interests: Declaration of Competing Interest The authors declare that they have no conflict of interest., (Copyright © 2024 Elsevier Ltd. All rights reserved.)- Published
- 2024
- Full Text
- View/download PDF
3. Ensemble Detection of DNA Engineering Signatures.
- Author
-
Adler A, Bader JS, Basnight B, Booth BW, Cai J, Cho E, Collins JH, Ge Y, Grothendieck J, Keating K, Marshall T, Persikov A, Scott H, Siegelmann R, Singh M, Taggart A, Toll B, Wan KH, Wyschogrod D, Yaman F, Young EM, Celniker SE, and Roehner N
- Subjects
- Sequence Analysis, DNA, DNA genetics
- Abstract
Synthetic biology is creating genetically engineered organisms at an increasing rate for many potentially valuable applications, but this potential comes with the risk of misuse or accidental release. To begin to address this issue, we have developed a system called GUARDIAN that can automatically detect signatures of engineering in DNA sequencing data, and we have conducted a blinded test of this system using a curated Test and Evaluation (T&E) data set. GUARDIAN uses an ensemble approach based on the guiding principle that no single approach is likely to be able to detect engineering with perfect accuracy. Critically, ensembling enables GUARDIAN to detect sequence inserts in 13 target organisms with a high degree of specificity that requires no subject matter expert (SME) review.
- Published
- 2024
- Full Text
- View/download PDF
4. An Examination of the Digital Parenting Profiles in Turkey.
- Author
-
Yaman F, Yurdakul IK, Akbulut Y, and Dönmez O
- Subjects
- Child, Female, Humans, Self Concept, Self Efficacy, Turkey, Male, Parenting, Parents
- Abstract
Internet use among children is increasing. This requires parents to develop digital parenting competencies as they are responsible for their children's well-being. In the current study the digital parenting self-efficacy perceptions of Turkish parents are examined with regard to the parental role, educational status, age, number of children, and Internet use experiences. Data were collected from a stratified sample of 7150 Turkish parents (i.e., only the mother or father in each family) from twenty-six provinces through the Digital Parenting Self-Efficacy Perception Scale. Descriptive statistics, comparison tests, and cluster analysis were used to analyze the data. The findings reveal that the participants' perceived digital parenting efficacy is high, and that perceptions change in terms of the parental role, educational status, age, number of children, and the Internet use experience., (© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.)
- Published
- 2024
- Full Text
- View/download PDF
5. Evaluation of neonatal outcomes according to the specific absorption rate values of phones used during pregnancy.
- Author
-
Büyükeren M and Karanfil Yaman F
- Abstract
Objective: The aim was to compare neonatal outcomes according to cell phone specific absorption rate (SAR) levels and daily time spent on cell phones by pregnant women., Material and Methods: Women who gave birth at Konya City Hospital between September 2020 and February 2021 were included in this retrospective study. Gestational ages, birth weight, birth length, head circumference, sex, 5-minute APGAR scores, neonate postpartum resuscitation requirement, delivery type, the model of phone used by the pregnant women, and the average time spent on the phone during a day were recorded. To determine the relation between the SAR values of the phones used and delivering a small for gestational age (SGA) baby, receiver operating characteristic curve analysis was performed., Results: In total 1495 pregnant women were included. The rate of delivering a SGA fetus was significantly higher in women who used phones with higher SAR values (p=0.001). The cut-off value for the SAR level was 1.23 W/kg with 69.3% sensitivity and 73.0% specificity (area under the curve: 0.685; 95% confidence interval: 0.643-0.726). No correlation was found between time spent on the phone and SGA birth rate. Although both phone SAR values and time spent on the phone were higher in the symmetrical SGA group compared to the asymmetrical SGA group, the difference was not significant (p>0.05). Although the women who had preterm delivery had higher phone SAR values and had spent more time on the phone compared to those who had term deliveries, the difference was again not significant (p>0.05)., Conclusion: As the SAR values of cell phones used during pregnancy increased, there was a trend towards delivering a SGA baby., Competing Interests: Conflict of Interest: No conflict of interest is declared by the authors., (Copyright© 2024 The Author. Published by Galenos Publishing House on behalf of Turkish-German Gynecological Association.)
- Published
- 2024
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.